A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia

PHASE3CompletedINTERVENTIONAL
Enrollment

427

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

September 10, 2020

Study Completion Date

September 10, 2020

Conditions
Presbyopia
Interventions
DRUG

Pilocarpine HCl Ophthalmic Solution

Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.

OTHER

Vehicle

Vehicle, one drop in each eye, once daily, for up to 30 days.

Trial Locations (35)

18702

Bucci Laser Vision, Wilkes-Barre

22046

Vision Consultants and Surgeons, Falls Church

29464

Waring Vision Institute, Mt. Pleasant

30260

Clayton Eye Center, Morrow

32256

Bowden Eye Associates, Jacksonville

32757

Mid Florida Eye Center, Mt. Dora

33309

South Florida Vision Center, Fort Lauderdale

33870

Newsom Eye & Laser Center, Sebring

34429

Benjamin Knox Lambright, MD, Crystal River

36301

Eye Center South, Dothan

37803

University Eye Surgeons, Maryville

38119

Total Eye Care, PA, Memphis

41017

Cincinnati Eye Institute, Edgewood

55420

Chu Laser Eye Institute, Bloomington

60016

The Midwest Center for Sight, Des Plaines

60046

Jacksoneye, Lake Villa

63128

Tekwani Vision Center, St Louis

64133

Silverstein Eye Centers, Kansas City

64154

Moyes Eye Center, Kansas City

66204

Heart of America Eyecare, Shawnee Mission

66762

Kannarr Eye Care, Pittsburg

76054

Texas Eye & Laser Ctr, Hurst

78731

Keystone Research ltd. at Texan Eye, Austin

79902

The Cataract and Glaucoma Center, El Paso

80120

Corneal Consultants of Colorado, Littleton

84403

Benjamin Travis Dastrup, MD, Ogden

85351

Walman Eye Center, Sun City

86301

M&M Eye Institute, Prescott

89117

Amel Youssef, OD, Las Vegas

89128

Debry Medical Services PC, Las Vegas

90067

Advanced Vision Care, Los Angeles

91204

Global Research Management, Glendale

91345

North Valley Eye Medical Group, Inc., Mission Hills

91702

Milton M. Hom, OD, FAAO, Azusa

92663

Eye Research Foundation, Newport Beach

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY

NCT03857542 - A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia | Biotech Hunter | Biotech Hunter